Chronic myeloid leukemia and resistance to tyrosine kinase inhibitors: ABL mutations, much ado about nothing?

被引：0

作者：

Gomez Casares, Maria Teresa ^{[1
]}

Leon, Leticia G. ^{[1
]}

机构：

[1] Hosp Univ Dr Negrin, Serv Hematol, Mol Biol Lab, Las Palmas Gran Canaria, Spain

来源：

MEDICINA CLINICA | 2013年 / 141卷 / 03期

关键词：

ACUTE LYMPHOBLASTIC-LEUKEMIA; GIMEMA WORKING PARTY; CHROMOSOMAL-ABNORMALITIES; IMATINIB; INTOLERANT; FREQUENCY; THERAPY; BCR/ABL; CML;

D O I：

10.1016/j.medcli.2012.12.011

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：111 / 113

页数：3

共 22 条

[1] Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia [J].

Apperley, Jane F. .

LANCET ONCOLOGY, 2007, 8 (11) :1018-1029

[2] Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet [J].

Baccarani, Michele ;

Cortes, Jorge ;

Pane, Fabrizio ;

Niederwieser, Dietger ;

Saglio, Giuseppe ;

Apperley, Jane ;

Cervantes, Francisco ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Francois ;

Hochhaus, Andreas ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Radich, Jerald ;

Simonsson, Bengt ;

Silver, Richard T. ;

Goldman, John ;

Hehlmann, Rudiger .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6041-6051

[3] THE CHRONIC MYELOGENOUS LEUKEMIA SPECIFIC P210-PROTEIN IS THE PRODUCT OF THE BCR/ABL HYBRID GENE [J].

BEN-NERIAH, Y ;

DALEY, GQ ;

MESMASSON, AM ;

WITTE, ON ;

BALTIMORE, D .

SCIENCE, 1986, 233 (4760) :212-214

[4] High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Grigg, A ;

Arthur, C ;

Taylor, K ;

Herrmann, R ;

Lynch, KP ;

Hughes, TP .

BLOOD, 2002, 99 (09) :3472-3475

[5] Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate [J].

Brave, Michael ;

Goodman, Vicki ;

Kaminskas, Edvardas ;

Farrell, Ann ;

Timmer, William ;

Pope, Sarah ;

Harapanhalli, Ravi ;

Saber, Haleh ;

Morse, David ;

Bullock, Julie ;

Men, Angela ;

Noory, Carol ;

Ramchandani, Roshni ;

Kenna, Leslie ;

Booth, Brian ;

Gobburu, Joga ;

Jiang, Xiaoping ;

Sridhara, Rajeshwari ;

Justice, Robert ;

Pazdur, Richard .

CLINICAL CANCER RESEARCH, 2008, 14 (02) :352-359

[6] Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation [J].

Cortes, Jorge ;

Lipton, Jeff H. ;

Rea, Delphine ;

Digumarti, Raghunadharao ;

Chuah, Charles ;

Nanda, Nisha ;

Benichou, Annie-Claude ;

Craig, Adam R. ;

Michallet, Mauricette ;

Nicolini, Franck E. ;

Kantarjian, Hagop .

BLOOD, 2012, 120 (13) :2573-2580

[7] Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias [J].

Cortes, Jorge E. ;

Kantarjian, Hagop ;

Shah, Neil P. ;

Bixby, Dale ;

Mauro, Michael J. ;

Flinn, Ian ;

O'Hare, Thomas ;

Hu, Simin ;

Narasimhan, Narayana I. ;

Rivera, Victor M. ;

Clackson, Tim ;

Turner, Christopher D. ;

Haluska, Frank G. ;

Druker, Brian J. ;

Deininger, Michael W. N. ;

Talpaz, Moshe .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (22) :2075-2088

[8] Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib [J].

Ernst, Thomas ;

Erben, Philipp ;

Mueller, Martin C. ;

Paschka, Peter ;

Schenk, Thomas ;

Hoffmann, Jana ;

Kreil, Sebastian ;

La Rosee, Paul ;

Hehlmann, Rudiger ;

Hochhaus, Andreas .

HAEMATOLOGICA, 2008, 93 (02) :186-192

[9]

Gomez-Casares M T, 2012, ONCOGENE, V18, P1, DOI DOI 10.1038/0NC.2012.246

[10] Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].

Gorre, ME ;

Mohammed, M ;

Ellwood, K ;

Hsu, N ;

Paquette, R ;

Rao, PN ;

Sawyers, CL .

SCIENCE, 2001, 293 (5531) :876-880

← 1 2 3 →